PRESS RELEASE published on 05/17/2023 at 12:30, 2 years 11 months ago Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
PRESS RELEASE published on 05/06/2023 at 12:30, 3 years ago Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
PRESS RELEASE published on 05/04/2023 at 12:30, 3 years ago Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
PRESS RELEASE published on 04/27/2023 at 12:30, 3 years ago Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
PRESS RELEASE published on 04/26/2023 at 12:30, 3 years ago Immunic to Participate in Investor and Scientific Conferences in May
PRESS RELEASE published on 04/05/2023 at 12:30, 3 years 1 month ago Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
PRESS RELEASE published on 03/02/2023 at 12:30, 3 years 2 months ago Immunic to Participate in Investor and Scientific Conferences in March
PRESS RELEASE published on 02/22/2023 at 12:30, 3 years 2 months ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
PRESS RELEASE published on 02/09/2023 at 12:30, 3 years 3 months ago Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
PRESS RELEASE published on 01/25/2023 at 12:30, 3 years 3 months ago Immunic to Participate in Scientific and Investor Conferences in February
Published on 05/09/2026 at 01:30, 13 hours 42 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 15 hours 12 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 18 hours 34 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 19 hours 59 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 20 hours 10 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 19 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:06, 1 day 20 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 18:17, 1 day 20 hours ago DESCRIPTION OF THE LOUIS HACHETTE GROUP SHARE BUYBACK PROGRAM 2026-2027
Published on 05/07/2026 at 17:45, 1 day 21 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
